Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Changes in gut-microbiota-related metabolites and long-term improvements in lipoprotein subspecies in overweight and obese adults: the POUNDS lost trial.

International journal of obesity (2005)

Heianza Y, Zhou T, He H, DiDonato JA, Bray GA, Sacks FM, Qi L.
PMID: 34426648
Int J Obes (Lond). 2021 Dec;45(12):2600-2607. doi: 10.1038/s41366-021-00939-7. Epub 2021 Aug 23.

BACKGROUND/OBJECTIVES: Alterations in gut microbiota have been linked to obesity and impaired lipid metabolism. Lipoproteins are heterogeneous, and lipoprotein subspecies containing apolipoprotein C-III (apoCIII) have adverse associations with obesity and related cardiometabolic abnormalities. We investigated associations of weight-loss diet-induced...

Cite
Heianza Y, Zhou T, He H, et al. Changes in gut-microbiota-related metabolites and long-term improvements in lipoprotein subspecies in overweight and obese adults: the POUNDS lost trial. Int J Obes (Lond). 2021;45(12):2600-2607doi: 10.1038/s41366-021-00939-7.
Heianza, Y., Zhou, T., He, H., DiDonato, J. A., Bray, G. A., Sacks, F. M., & Qi, L. (2021). Changes in gut-microbiota-related metabolites and long-term improvements in lipoprotein subspecies in overweight and obese adults: the POUNDS lost trial. International journal of obesity (2005), 45(12), 2600-2607. https://doi.org/10.1038/s41366-021-00939-7
Heianza, Yoriko, et al. "Changes in gut-microbiota-related metabolites and long-term improvements in lipoprotein subspecies in overweight and obese adults: the POUNDS lost trial." International journal of obesity (2005) vol. 45,12 (2021): 2600-2607. doi: https://doi.org/10.1038/s41366-021-00939-7
Heianza Y, Zhou T, He H, DiDonato JA, Bray GA, Sacks FM, Qi L. Changes in gut-microbiota-related metabolites and long-term improvements in lipoprotein subspecies in overweight and obese adults: the POUNDS lost trial. Int J Obes (Lond). 2021 Dec;45(12):2600-2607. doi: 10.1038/s41366-021-00939-7. Epub 2021 Aug 23. PMID: 34426648; PMCID: PMC8608703.
Copy Download .nbib Format: NLM
Effects of Smoking and Smoking Cessation on the Intestinal Microbiota.

Journal of clinical medicine

Sublette MG, Cross TL, Korcarz CE, Hansen KM, Murga-Garrido SM, Hazen SL, Wang Z, Oguss MK, Rey FE, Stein JH.
PMID: 32937839
J Clin Med. 2020 Sep 14;9(9). doi: 10.3390/jcm9092963.

We evaluated associations of smoking heaviness markers and the effects of smoking cessation on the intestinal microbiota and cardiovascular disease risk factors in current smokers undertaking a quit attempt. Participants were current smokers enrolled in a prospective randomized clinical...

Cite
Sublette MG, Cross TL, Korcarz CE, et al. Effects of Smoking and Smoking Cessation on the Intestinal Microbiota. J Clin Med. 2020;9(9)doi: 10.3390/jcm9092963.
Sublette, M. G., Cross, T. L., Korcarz, C. E., Hansen, K. M., Murga-Garrido, S. M., Hazen, S. L., Wang, Z., Oguss, M. K., Rey, F. E., & Stein, J. H. (2020). Effects of Smoking and Smoking Cessation on the Intestinal Microbiota. Journal of clinical medicine, 9(9), . https://doi.org/10.3390/jcm9092963
Sublette, Marcus G, et al. "Effects of Smoking and Smoking Cessation on the Intestinal Microbiota." Journal of clinical medicine vol. 9,9 (2020). doi: https://doi.org/10.3390/jcm9092963
Sublette MG, Cross TL, Korcarz CE, Hansen KM, Murga-Garrido SM, Hazen SL, Wang Z, Oguss MK, Rey FE, Stein JH. Effects of Smoking and Smoking Cessation on the Intestinal Microbiota. J Clin Med. 2020 Sep 14;9(9). doi: 10.3390/jcm9092963. PMID: 32937839; PMCID: PMC7564179.
Copy Download .nbib Format: NLM
Marked elevation in plasma trimethylamine-N-oxide (TMAO) in patients with mitochondrial disorders treated with oral l-carnitine.

Molecular genetics and metabolism reports

Vallance HD, Koochin A, Branov J, Rosen-Heath A, Bosdet T, Wang Z, Hazen SL, Horvath G.
PMID: 30023305
Mol Genet Metab Rep. 2018 May 03;15:130-133. doi: 10.1016/j.ymgmr.2018.04.005. eCollection 2018 Jun.

Oral supplementation with l-carnitine is a common therapeutic modality for mitochondrial disorders despite limited evidence of efficacy. Recently, a number of studies have demonstrated that a gut microbiota-dependent metabolite of l-carnitine, trimethylamine oxide (TMAO), is an independent and dose-dependent...

Cite
Vallance HD, Koochin A, Branov J, et al. Marked elevation in plasma trimethylamine-N-oxide (TMAO) in patients with mitochondrial disorders treated with oral l-carnitine. Mol Genet Metab Rep. 2018;15:130-133doi: 10.1016/j.ymgmr.2018.04.005.
Vallance, H. D., Koochin, A., Branov, J., Rosen-Heath, A., Bosdet, T., Wang, Z., Hazen, S. L., & Horvath, G. (2018). Marked elevation in plasma trimethylamine-N-oxide (TMAO) in patients with mitochondrial disorders treated with oral l-carnitine. Molecular genetics and metabolism reports, 15130-133. https://doi.org/10.1016/j.ymgmr.2018.04.005
Vallance, H D, et al. "Marked elevation in plasma trimethylamine-N-oxide (TMAO) in patients with mitochondrial disorders treated with oral l-carnitine." Molecular genetics and metabolism reports vol. 15 (2018): 130-133. doi: https://doi.org/10.1016/j.ymgmr.2018.04.005
Vallance HD, Koochin A, Branov J, Rosen-Heath A, Bosdet T, Wang Z, Hazen SL, Horvath G. Marked elevation in plasma trimethylamine-N-oxide (TMAO) in patients with mitochondrial disorders treated with oral l-carnitine. Mol Genet Metab Rep. 2018 May 03;15:130-133. doi: 10.1016/j.ymgmr.2018.04.005. eCollection 2018 Jun. PMID: 30023305; PMCID: PMC6047224.
Copy Download .nbib Format: NLM
Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes.

Diabetes & metabolism

León-Mimila P, Villamil-Ramírez H, Li XS, Shih DM, Hui ST, Ocampo-Medina E, López-Contreras B, Morán-Ramos S, Olivares-Arevalo M, Grandini-Rosales P, Macías-Kauffer L, González-González I, Hernández-Pando R, Gómez-Pérez F, Campos-Pérez F, Aguilar-Salinas C, Larrieta-Carrasco E, Villarreal-Molina T, Wang Z, Lusis AJ, Hazen SL, Huertas-Vazquez A, Canizales-Quinteros S.
PMID: 32791310
Diabetes Metab. 2021 Mar;47(2):101183. doi: 10.1016/j.diabet.2020.07.010. Epub 2020 Aug 10.

AIMS: Trimethylamine N-oxide (TMAO), choline and betaine serum levels have been associated with metabolic diseases including type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD). These associations could be mediated by insulin resistance. However, the relationships among these...

Cite
León-Mimila P, Villamil-Ramírez H, Li XS, et al. Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes. Diabetes Metab. 2020;47(2):101183doi: 10.1016/j.diabet.2020.07.010.
León-Mimila, P., Villamil-Ramírez, H., Li, X. S., Shih, D. M., Hui, S. T., Ocampo-Medina, E., López-Contreras, B., Morán-Ramos, S., Olivares-Arevalo, M., Grandini-Rosales, P., Macías-Kauffer, L., González-González, I., Hernández-Pando, R., Gómez-Pérez, F., Campos-Pérez, F., Aguilar-Salinas, C., Larrieta-Carrasco, E., Villarreal-Molina, T., Wang, Z., Lusis, A. J., Hazen, S. L., Huertas-Vazquez, A., & Canizales-Quinteros, S. (2021). Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes. Diabetes & metabolism, 47(2), 101183. https://doi.org/10.1016/j.diabet.2020.07.010
León-Mimila, P, et al. "Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes." Diabetes & metabolism vol. 47,2 (2021): 101183. doi: https://doi.org/10.1016/j.diabet.2020.07.010
León-Mimila P, Villamil-Ramírez H, Li XS, Shih DM, Hui ST, Ocampo-Medina E, López-Contreras B, Morán-Ramos S, Olivares-Arevalo M, Grandini-Rosales P, Macías-Kauffer L, González-González I, Hernández-Pando R, Gómez-Pérez F, Campos-Pérez F, Aguilar-Salinas C, Larrieta-Carrasco E, Villarreal-Molina T, Wang Z, Lusis AJ, Hazen SL, Huertas-Vazquez A, Canizales-Quinteros S. Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes. Diabetes Metab. 2021 Mar;47(2):101183. doi: 10.1016/j.diabet.2020.07.010. Epub 2020 Aug 10. PMID: 32791310; PMCID: PMC8018562.
Copy Download .nbib Format: NLM
High Betaine, a Trimethylamine N-Oxide Related Metabolite, Is Prospectively Associated with Low Future Risk of Type 2 Diabetes Mellitus in the PREVEND Study.

Journal of clinical medicine

Garcia E, Osté MCJ, Bennett DW, Jeyarajah EJ, Shalaurova I, Gruppen EG, Hazen SL, Otvos JD, Bakker SJL, Dullaart RPF, Connelly MA.
PMID: 31683780
J Clin Med. 2019 Nov 01;8(11). doi: 10.3390/jcm8111813.

BACKGROUND: Gut microbiota-related metabolites, trimethylamine-N-oxide (TMAO), choline, and betaine, have been shown to be associated with cardiovascular disease (CVD) risk. Moreover, lower plasma betaine concentrations have been reported in subjects with type 2 diabetes mellitus (T2DM). However, few studies...

Cite
Garcia E, Osté MCJ, Bennett DW, et al. High Betaine, a Trimethylamine N-Oxide Related Metabolite, Is Prospectively Associated with Low Future Risk of Type 2 Diabetes Mellitus in the PREVEND Study. J Clin Med. 2019;8(11)doi: 10.3390/jcm8111813.
Garcia, E., Osté, M. C. J., Bennett, D. W., Jeyarajah, E. J., Shalaurova, I., Gruppen, E. G., Hazen, S. L., Otvos, J. D., Bakker, S. J. L., Dullaart, R. P. F., & Connelly, M. A. (2019). High Betaine, a Trimethylamine N-Oxide Related Metabolite, Is Prospectively Associated with Low Future Risk of Type 2 Diabetes Mellitus in the PREVEND Study. Journal of clinical medicine, 8(11), . https://doi.org/10.3390/jcm8111813
Garcia, Erwin, et al. "High Betaine, a Trimethylamine N-Oxide Related Metabolite, Is Prospectively Associated with Low Future Risk of Type 2 Diabetes Mellitus in the PREVEND Study." Journal of clinical medicine vol. 8,11 (2019). doi: https://doi.org/10.3390/jcm8111813
Garcia E, Osté MCJ, Bennett DW, Jeyarajah EJ, Shalaurova I, Gruppen EG, Hazen SL, Otvos JD, Bakker SJL, Dullaart RPF, Connelly MA. High Betaine, a Trimethylamine N-Oxide Related Metabolite, Is Prospectively Associated with Low Future Risk of Type 2 Diabetes Mellitus in the PREVEND Study. J Clin Med. 2019 Nov 01;8(11). doi: 10.3390/jcm8111813. PMID: 31683780; PMCID: PMC6912391.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries